Skip to main content

Acute Bacterial Skin and Skin Structure Infection (ABSSSI)

1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

TenNor Therapeutics
TenNor TherapeuticsChina - Suzhou
1 program
1
TNP-2092 for injectionPhase 11 trial
Active Trials
NCT06394518Completed32Est. Feb 2023

Trial Timeline

Clinical trial activity over time

2022
2023
2024
2025
2026
TenNor TherapeuticsTNP-2092 for injection

Clinical Trials (1)

Total enrollment: 32 patients across 1 trials

NCT06394518TenNor TherapeuticsTNP-2092 for injection

Phase 1, Single-Dose and Multiple-Dose Continuous Intravenous Infusions of TNP-2092 for Injection in Healthy Chinese Participants

Start: Jul 2022Est. completion: Feb 202332 patients
Phase 1Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.